January 8, 2019 07:29 AM EST

Championed by AbbVie, immuno-neurology player Alector maps $150M IPO

Natalie Grover

Reporter

Endorsed by AbbVie, and under the leadership of Genentech veteran Arnon Rosenthal, San Francisco-based biotech Alector has charted a path toward a $150 million IPO …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Championed by AbbVie, immuno-neurology player Alector maps $150M IPO

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Cham­pi­oned by Ab­b­Vie, im­muno-neu­rol­o­gy play­er Alec­tor maps $150M IPO

Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Championed by AbbVie, immuno-neurology player Alector maps $150M IPO